Author

B. Fabre

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cell type annotation· 2 Organism:human· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:differential expression· 1

Frequent Co-Authors

O. Burlet-Schiltz· 2 shared A. Deshpande· 1 shared A. I. Lamond· 1 shared A. J. Deshpande· 1 shared A. Khateb· 1 shared A. Montigny· 1 shared B. Jonik-Nowak· 1 shared C. Bonne-Andrea· 1 shared

Activity by Year

2018-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 15 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

O. Burlet-Schiltz

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

In depth exploration of the alternative proteome of Drosophila melanogaster

B. Fabre, S. A. Choteau, C. Duboe, C. Pichereaux, A. Montigny, D. Korona, M. J. Deery, M. Camus, C. Brun, O. Burlet-Schiltz, S. Russell, C. Jean-Philippe, K. S. Lilley, S. Plaza

This study identifies 401 alternative proteins in Drosophila melanogaster through peptidomics, showing some are more abundant than canonical proteins and exhibit developmentally regulated or stress-induced expression.

bioRxiv · Mar 16, 2022Biochemistry

RNF5 Regulation of RBBP4 Defines Acute Myeloid Leukemia Growth and Susceptibility to Histone Deacetylase Inhibitors

A. Khateb, A. Deshpande, Y. Feng, J. S. Lee, I. Lazar, B. Fabre, Y. Li, D. Finlay, Y. Fujita, T. Zhang, J. Yin, I. Pass, I. Livneh, C. Burian, J. R. Mason, , Z. A. Ronai

This study shows RNF5 promotes AML growth by regulating RBBP4 and epigenetic pathways, and its inhibition enhances sensitivity to HDAC inhibitors, suggesting it as a therapeutic target and biomarker.

bioRxiv · Oct 25, 2020Cancer Biology

PIP30/FAM192A is a novel regulator of the nuclear proteasome activator PA28gamma

B. Jonik-Nowak, T. Menneteau, D. Fesquet, V. Baldin, C. Bonne-Andrea, F. Mechali, B. Fabre, P. Boisguerin, S. De Rossi, C. Henriquet, M. Pugniere, M. Ducoux-Petit, O. Burlet-Schiltz, A. I. Lamond, P. Fort, , O. Coux

This paper identifies PIP30/FAM192A as a novel cofactor of PA28gamma, showing it binds to PA28gamma and modulates its interactions with the 20S proteasome and coilin.

bioRxiv · Mar 27, 2018Cell Biology